Synthetic Peptides of Epstein-Barr Virus-major Envelope Glycoprotein-350/220 do not Prevent Infection in a Rabbit Epstein-Barr Virus Infection Model
- *Corresponding Author:
- Kaoru Kato
Division of Molecular Pathology, Department of Pathology
Faculty of Medicine, Tottori University
Yonago, Tottori, 683-8503, Japan
Tel: (+81) 859-38-6063
Fax: (+81) 859-38-6060
E-mail: [email protected]
Received date: July 23, 2012; Accepted date: September 27, 2012; Published date: October 03, 2012
Citation: Kato K, Sano H, Nagata K, Sugihara H, Kanai K, et al. (2012) Synthetic Peptides of Epstein–Barr Virus-major Envelope Glycoprotein-350/220 do not Prevent Infection in a Rabbit Epstein–Barr Virus Infection Model. J Vaccines Vaccin 3:150. doi:10.4172/2157-7560.1000150
Copyright: © 2012 Kato K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Epstein–Barr virus (EBV) is a ubiquitous herpes virus that usually infects humans asymptomatically, occasionally inducing various EBV-associated diseases, including infectious mononucleosis (IM), chronic active EBV infection, and different types of malignant tumors. A history of IM is associated with a 3-fold increased risk for subsequent EBV-related Hodgkin lymphoma. In immunocompromised individuals or transplant patients, EBV presents a high risk for morbidity and mortality, although prophylactic vaccination against EBV might contribute to reduce this risk. In this study, we used a rabbit EBV infection model to determine whether vaccination with synthesized peptides based on gp350/220 sequences could effectively prevent EBV infection or decrease the rate or degree of EBV infection. Six rabbits vaccinated with EBV gp350-peptides and four controls were challenged with a minimum dose of EBV infection; EBV-DNAs or EBV-RNAs were detected in 5/6 and 4/4 rabbits, respectively. This suggested that a gp350-peptide vaccine could not prevent primary EBV infections in rabbits and indicated the presence of EBV infection routes or mechanisms in rabbits other than the gp350-CD21 interaction observed in EBV infection of human B-cells. However, this vaccine probably has the efficacy to control the viral loads in inoculated rabbits, because 5 out of 6 vaccinated rabbits showed no detectable EBV-DNA in their blood and either no or only few EBER-1-positive lymphocytes in the lymphoid tissues. This vaccine was immunogenic; however, developing other improved vaccines or adjuvants will be necessary to reduce EBV-related diseases.